Literature DB >> 12571858

Identification and characterization of SmD183-119-reactive T cells that provide T cell help for pathogenic anti-double-stranded DNA antibodies.

Gabriela Riemekasten1, Dirk Langnickel, Fanny M Ebling, George Karpouzas, Jatinderpal Kalsi, Gunda Herberth, Betty P Tsao, Peter Henklein, Sven Langer, Gerd-R Burmester, Andreas Radbruch, Falk Hiepe, Bevra H Hahn.   

Abstract

OBJECTIVE: The C-terminal peptide of amino acids 83-119 of the SmD1 protein is a target of the autoimmune response in human and murine lupus. This study was undertaken to test the hypothesis that SmD1(83-119)-reactive T cells play a crucial role in the generation of pathogenic anti-double-stranded DNA (anti-dsDNA) antibodies.
METHODS: Splenic or lymph node T cells derived from unmanipulated as well as SmD1(83-119)-immunized NZB/NZW mice were analyzed in vitro by enzyme-linked immunospot (ELISpot) assay to determine T cell help for anti-dsDNA generation induced by the SmD1(83-119) peptide. Cytokines expressed by these T cells were measured by ELISpot assay, enzyme-linked immunosorbent assay, and flow cytometry. SmD1(83-119)- and ovalbumin-specific T cell lines were generated and characterized.
RESULTS: The SmD1(83-119) peptide, but not the control peptides, significantly increased the in vitro generation of anti-dsDNA antibodies in cultures from unmanipulated NZB/NZW mice. Interferon-gamma (IFNgamma), interleukin-2 (IL-2), IL-4, transforming growth factor beta, and IL-10 production increased in response to the peptide in young mice; only IFNgamma and IL-2 were increased in older, diseased mice. Activation of SmD1(83-119)-reactive T cells by immunization of NZB/NZW mice resulted in elevated anti-dsDNA synthesis and, later, increased antibodies to SmD1(83-119). Most cells in SmD1(83-119)-specific CD4+ T cell lines helping both antibodies had increased intracellular expression of IFNgamma, and most expressed both IFNgamma and IL-4.
CONCLUSION: The SmD1(83-119) peptide plays an important role in generating T cell help for autoantibodies, including anti-dsDNA, and activates different subsets of T cells as defined by distinct cytokine expression. This peptide is an interesting target structure for the modulation of autoreactive T cells, and its characterization may contribute to our understanding of the role of autoantigen-reactive T cells in the pathogenesis of SLE.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12571858     DOI: 10.1002/art.10762

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  6 in total

Review 1.  T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens.

Authors:  Syamal K Datta; Li Zhang; Luting Xu
Journal:  J Mol Med (Berl)       Date:  2005-01-04       Impact factor: 4.599

2.  The binding of lupus-derived autoantibodies to the C-terminal peptide (83-119) of the major SmD1 autoantigen can be mediated by double-stranded DNA and nucleosomes.

Authors:  J W Dieker; C C Van Bavel; G Riemekasten; J H Berden; J van der Vlag
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

3.  Induction of pathogenic anti-dsDNA antibodies is controlled on the level of B cells in a non-lupus prone mouse strain.

Authors:  Dirk Langnickel; Philipp Enghard; Claudia Klein; Reinmar Undeutsch; Berthold Hocher; R Manz; G R Burmester; Gabriela Riemekasten
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

4.  A Central Role for HLA-DR3 in Anti-Smith Antibody Responses and Glomerulonephritis in a Transgenic Mouse Model of Spontaneous Lupus.

Authors:  Vaidehi R Chowdhary; Chao Dai; Ashenafi Y Tilahun; Julie A Hanson; Michele K Smart; Joseph P Grande; Govindarajan Rajagopalan; Shu-Man Fu; Chella S David
Journal:  J Immunol       Date:  2015-10-16       Impact factor: 5.422

5.  Differential responses to Smith D autoantigen by mice with HLA-DR and HLA-DQ transgenes: dominant responses by HLA-DR3 transgenic mice with diversification of autoantibodies to small nuclear ribonucleoprotein, double-stranded DNA, and nuclear antigens.

Authors:  Chao Jiang; Umesh S Deshmukh; Felicia Gaskin; Harini Bagavant; Julie Hanson; Chella S David; Shu Man Fu
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

Review 6.  Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus.

Authors:  Sean Robinson; Ranjeny Thomas
Journal:  Front Immunol       Date:  2021-07-16       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.